Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.31 - $0.73 $935 - $2,202
-3,017 Reduced 50.54%
2,952 $1,000
Q4 2022

Feb 14, 2023

BUY
$0.27 - $5.75 $4 - $97
17 Added 0.29%
5,969 $1,000
Q3 2022

Nov 14, 2022

SELL
$0.59 - $5.57 $3,954 - $37,330
-6,702 Reduced 52.96%
5,952 $4,000
Q2 2022

Oct 27, 2022

SELL
$0.6 - $1.14 $6 - $12
-11 Reduced 0.09%
12,654 $10,000
Q2 2022

Aug 15, 2022

SELL
$0.6 - $1.14 $6 - $12
-11 Reduced 0.09%
12,654 $10,000
Q1 2022

Oct 27, 2022

BUY
$0.88 - $1.37 $9 - $15
11 Added 0.09%
12,665 $13,000
Q1 2022

May 13, 2022

BUY
$0.88 - $1.37 $9 - $15
11 Added 0.09%
12,665 $13,000
Q4 2021

Feb 14, 2022

BUY
$1.27 - $2.08 $9,495 - $15,552
7,477 Added 144.43%
12,654 $16,000
Q3 2021

Nov 15, 2021

BUY
$1.73 - $5.3 $8,956 - $27,438
5,177 New
5,177 $11,000

About Xenetic Biosciences, Inc.


  • Ticker XBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,166,600
  • Market Cap $64.6M
  • Description
  • Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...
More about XBIO
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.